Brought to you by 
Mayne Pharma licenses generics from Pliva
Mar 2005
Executive Summary
Specialty pharmaceuticals company Pliva DD and Mayne Pharma (generics) have entered into an agreement for the development and marketing of Pliva's lead generics programs--erythropoietin (EPO) and granulocyte colony stimulating factor (G-CSF).
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com